Development and external validation of an algorithm for self-identification of risk for microvascular complications in patients with type 1 diabetes.

IF 5.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes, Obesity & Metabolism Pub Date : 2025-02-01 Epub Date: 2024-11-25 DOI:10.1111/dom.16068
Wei Liu, Xiaodan Hu, Yayu Fang, Shenda Hong, Yu Zhu, Mingxia Zhang, Siqian Gong, Xiangqing Wang, Chu Lin, Rui Zhang, Sai Yin, Juan Li, Yongran Huo, Xiaoling Cai, Linong Ji
{"title":"Development and external validation of an algorithm for self-identification of risk for microvascular complications in patients with type 1 diabetes.","authors":"Wei Liu, Xiaodan Hu, Yayu Fang, Shenda Hong, Yu Zhu, Mingxia Zhang, Siqian Gong, Xiangqing Wang, Chu Lin, Rui Zhang, Sai Yin, Juan Li, Yongran Huo, Xiaoling Cai, Linong Ji","doi":"10.1111/dom.16068","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Microvascular complications, such as diabetic retinopathy (DR), diabetic nephropathy (DN) and diabetic peripheral neuropathy (DPN), are common and serious outcomes of inadequately managed type 1 diabetes (T1D). Timely detection and intervention in these complications are crucial for improving patient outcomes. This study aimed to develop and externally validate machine learning (ML) models for self-identification of microvascular complication risks in T1D population.</p><p><strong>Materials and methods: </strong>Utilizing data from the Chinese Type 1 Diabetes Comprehensive Care Pathway program, 911 T1D patients and 15 patient self-reported variables were included. Combined with XGBoost algorithm and cross-validation, self-identification models were constructed with 5 variables selected by feature importance ranking. For external validation, an online survey was conducted within a nationwide T1D online community (N = 157). The area under the receiver-operating-characteristic curve (AUROC) was adopted as the main metric to evaluate the model performance. The SHapley Additive exPlanation was utilized for model interpretation.</p><p><strong>Results: </strong>The prevalence rates of microvascular complications in the development set and external validation set were as follows: DR 7.0% and 12.7% (p = 0.013), DN 5.9% and 3.2% (p = 0.162) and DPN 10.5% and 20.4% (p < 0.001). The models demonstrated the AUROC values of 0.889 for DR, 0.844 for DN and 0.839 for DPN during internal validation. For external validation, the AUROC values achieved 0.762 for DR, 0.718 for DN and 0.721 for DPN.</p><p><strong>Conclusions: </strong>ML models, based on self-reported data, have the potential to serve as a self-identification tool, empowering T1D patients to understand their risks outside of hospital settings and encourage early engagement with healthcare services.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"740-749"},"PeriodicalIF":5.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16068","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Microvascular complications, such as diabetic retinopathy (DR), diabetic nephropathy (DN) and diabetic peripheral neuropathy (DPN), are common and serious outcomes of inadequately managed type 1 diabetes (T1D). Timely detection and intervention in these complications are crucial for improving patient outcomes. This study aimed to develop and externally validate machine learning (ML) models for self-identification of microvascular complication risks in T1D population.

Materials and methods: Utilizing data from the Chinese Type 1 Diabetes Comprehensive Care Pathway program, 911 T1D patients and 15 patient self-reported variables were included. Combined with XGBoost algorithm and cross-validation, self-identification models were constructed with 5 variables selected by feature importance ranking. For external validation, an online survey was conducted within a nationwide T1D online community (N = 157). The area under the receiver-operating-characteristic curve (AUROC) was adopted as the main metric to evaluate the model performance. The SHapley Additive exPlanation was utilized for model interpretation.

Results: The prevalence rates of microvascular complications in the development set and external validation set were as follows: DR 7.0% and 12.7% (p = 0.013), DN 5.9% and 3.2% (p = 0.162) and DPN 10.5% and 20.4% (p < 0.001). The models demonstrated the AUROC values of 0.889 for DR, 0.844 for DN and 0.839 for DPN during internal validation. For external validation, the AUROC values achieved 0.762 for DR, 0.718 for DN and 0.721 for DPN.

Conclusions: ML models, based on self-reported data, have the potential to serve as a self-identification tool, empowering T1D patients to understand their risks outside of hospital settings and encourage early engagement with healthcare services.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
1 型糖尿病患者微血管并发症风险自我识别算法的开发和外部验证。
目的:微血管并发症,如糖尿病视网膜病变(DR)、糖尿病肾病(DN)和糖尿病周围神经病变(DPN),是管理不当的 1 型糖尿病(T1D)常见的严重并发症。及时发现和干预这些并发症对改善患者预后至关重要。本研究旨在开发并从外部验证机器学习(ML)模型,用于T1D人群微血管并发症风险的自我识别:利用中国1型糖尿病综合治疗路径项目的数据,纳入了911名T1D患者和15个患者自我报告的变量。结合 XGBoost 算法和交叉验证,通过特征重要性排序筛选出 5 个变量,构建了自我识别模型。为了进行外部验证,在全国范围内的 T1D 在线社区(N = 157)进行了在线调查。接受者工作特征曲线下面积(AUROC)是评估模型性能的主要指标。结果表明,微血管并发症的患病率为 0.5%,而 T1D 患者的患病率为 0.5%:开发集和外部验证集的微血管并发症发生率如下:DR 7.0% 和 12.0%:DR为7.0%和12.7%(P = 0.013),DN为5.9%和3.2%(P = 0.162),DPN为10.5%和20.4%(P 结论:微血管并发症的发生率与患者的自我评估有关:基于自我报告数据的 ML 模型有可能成为一种自我识别工具,使 T1D 患者有能力了解他们在医院以外的风险,并鼓励他们尽早参与医疗服务。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
期刊最新文献
Body weight variability as a predictor of cardiovascular outcomes in type 1 diabetes: A nationwide cohort study. Future directions for quality of life research with second-generation GLP-1RAs for obesity. Safety and effects of acetylated and butyrylated high-amylose maize starch on youths recently diagnosed with type 1 diabetes: A pilot study. Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1